Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the effectiveness of atogepant for the preventive treatment of migraine in adult patients in the UK.
Atogepant is an approved drug for preventive treatment of migraine in adults. Approximately 200 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in the UK.
Participants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 48.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.
Physician-confirmed diagnosis of migraine, classified as either episodic or chronic.
Have at least 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders 3rd edition (ICHD-3), 2018.
Without prior exposure to atogepant who are being prescribed atogepant in primary care for the prophylaxis of migraine with at least 4 migraine days per month.
Decision to initiate atogepant was made by a prescribing general practitioner (GP) or appropriate primary care health care professional (HCP) within a primary care setting, prior to and independent of any decision to approach the patient regarding participation in the study.
Previously exposed to atogepant as routine therapy before the study period or from clinical trials experience prior to entry.
Enrolled in any interventional studies that may include investigational compounds for migraine.
Initiated on atogepant in secondary care and subsequently maintained in primary care.
Initiated on atogepant in primary care following specialist input via an 'advice and guidance' pathway.